Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02181517 · ClinicalTrials.gov registry record · Phase 2
A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
A Phase 2 study of Macular Degeneration, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT02181517 is a Phase 2 study of Macular Degeneration that has completed, run by Allergan. The registered enrollment target is 25 participants, below the 178-participant average among 26 other Macular Degeneration trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02181517, a Phase 2 study of Macular Degeneration, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration to establish comparability between Japanese and non-Japanese.
Conditions Studied
Interventions
- DRUG ranibizumab
- DRUG abicipar pegol
- OTHER sham procedure
Study Locations (1)
Arizona
- - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02181517
The ClinicalTrials.gov registry entry for NCT02181517 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 178-participant average among 26 other Macular Degeneration trials with a reported enrollment target (86% lower). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Macular Degeneration appearing as the primary indexed condition, and to 3 interventions - of which ranibizumab is the first listed.
NCT02181517 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT02181517 about?
NCT02181517 is a clinical study titled "A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration". This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration to establish comparability between Japanese and non-Japanese.
What is the current status of trial NCT02181517?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2014-07. Estimated completion is 2015-03.
What conditions does trial NCT02181517 study?
This clinical trial studies the following conditions: Macular Degeneration.
What interventions are being tested in trial NCT02181517?
The interventions under investigation include: ranibizumab (DRUG), abicipar pegol (DRUG), sham procedure (OTHER).
Who is sponsoring clinical trial NCT02181517?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02181517 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 2
-
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
ACTIVE NOT RECRUITING · Phase 2
-
Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD
COMPLETED · Phase 2
-
Factors in Learning And Plasticity: Macular Degeneration
RECRUITING · NA
-
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
RECRUITING · Early Phase 1
-
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.